Logo yposkesi
waves image

Yposkesi selected by Orchard Therapeutics to produce lentiviral vectors for gene therapies in clinical trials

Yposkesi brings to Orchard Therapeutics’ projects expertise and production capacity. Under the agreement, Yposkesi will produce lentiviral vector batches to meet Orchard’s needs for clinical trials in primary immune deficiencies including X-linked chronic granulomatous (X-CGD) disease.

CP_YPOSKESI_Orchard Therapeutics